The company said its total revenues increased 7% to $8.3 billion and $23.1 billion for the 3 and 9 months ended September 30, 2026, respectively, compared with the same periods a year earlier. It cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.

10-QQuarterly reportFiled Oct 30, 2026Period of report Sep 30, 2026Summary published (UTC) Oct 30, 2026

Key points

AI summary

The company said its total revenues increased 7% to $8.3 billion and $23.1 billion for the 3 and 9 months ended September 30, 2026, respectively, compared with the same periods a year earlier. It cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.
Gilead said it reported net income of $2.4 billion (diluted earnings per share of $1.94) for the 3 months, and a net loss of $6.0 billion (diluted loss per share of $4.87) for the 9 months. The company cited higher acquired IPR&D expenses tied to its acquisitions of Arcellx, Tubulis and Ouro Medicines, and a $1.75 billion IPR&D impairment charge, as factors behind the 9-month decline.
The company said it announced the discontinuation of the Phase 3 EVOKE-03 study in June 2026. Because it expected no future cash flows from the NSCLC IPR&D intangible asset, it recognized an impairment charge of the remaining balance of $1.75 billion, the company said. The charge was recorded in the 9-month period ended in 2026.
The company said net cash provided by operating activities increased in the 9 months of 2026 compared with the same period a year earlier. It cited lower income tax payments, collections on higher product sales, receipt of the Lakefront collaboration payment and lower inventory spend as the main drivers. It said the main driver of the change in net cash used in investing activities over the same period was payments related to the acquisitions of Arcellx, Tubulis and Ouro Medicines.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Quarterly and 9-Month Revenue Up 7%, Led by HIV Products

The company said its total revenues increased 7% to $8.3 billion and $23.1 billion for the 3 and 9 months ended September 30, 2026, respectively, compared with the same periods a year earlier. It cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.

Source · Based on the MD&A text of the filing

Third-Quarter Net Income $2.4 billion; 9-Month Net Loss $6.0 billion

Gilead said it reported net income of $2.4 billion (diluted earnings per share of $1.94) for the 3 months, and a net loss of $6.0 billion (diluted loss per share of $4.87) for the 9 months. The company cited higher acquired IPR&D expenses tied to its acquisitions of Arcellx, Tubulis and Ouro Medicines, and a $1.75 billion IPR&D impairment charge, as factors behind the 9-month decline.

Source · Based on the MD&A text of the filing

$1.75 billion IPR&D Impairment Charge Recognized

The company said it announced the discontinuation of the Phase 3 EVOKE-03 study in June 2026. Because it expected no future cash flows from the NSCLC IPR&D intangible asset, it recognized an impairment charge of the remaining balance of $1.75 billion, the company said. The charge was recorded in the 9-month period ended in 2026.

Source · Based on the MD&A text of the filing

Operating cash flow rose over 9 months; Gilead cited acquisition payments in investing activities

The company said net cash provided by operating activities increased in the 9 months of 2026 compared with the same period a year earlier. It cited lower income tax payments, collections on higher product sales, receipt of the Lakefront collaboration payment and lower inventory spend as the main drivers. It said the main driver of the change in net cash used in investing activities over the same period was payments related to the acquisitions of Arcellx, Tubulis and Ouro Medicines.

Source · Based on the MD&A text of the filing

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.